Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma (HNSCC)

The EGFR monoclonal antibody cetuximab is the only approved targeted agent for treating head and neck squamous cell carcinoma (HNSCC). Yet resistance to cetuximab has hindered its activity in this disease. Intrinsic or compensatory HER3 signaling may contribute to cetuximab resistance. To investigat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Jiang, Ning, Wang, Dongsheng, Hu, Zhongliang, Shin, Hyung Ju C., Qian, Guoqing, Rahman, Mohammad Aminur, Zhang, Hongzheng, Amin, A.R.M. Ruhul, Nannapaneni, Sreenivas, Wang, Xiaojing, Chen, Zhengjia, Garcia, Gabriela, MacBeath, Gavin, Shin, Dong M., Khuri, Fadlo R., Ma, Jun, Chen, Zhuo G., Saba, Nabil F.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4090261/
https://ncbi.nlm.nih.gov/pubmed/24748655
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-13-1093
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars